Vespa Capital has announced the completion of the sale of BioPhorum Operations Group Limited (“BioPhorum”) to Five Arrows Growth Capital, part of the European private equity arm of Rothschild & Co.
BioPhorum facilitates the pre-competitive collaboration between global biopharmaceutical and MedTech companies enabling participants to reduce costs of manufacturing, develop industry standards, and accelerate progress across the industry. The company works with over 100 members including specialist suppliers, and mid-sized biopharmaceutical, cell and gene therapy, and MedTech companies.
Since investing in the business in June 2018, Vespa Capital supported BioPhorum in the development of the management team, including the hiring of a CEO and FD, a re-platform of the IT infrastructure including the financial and reporting systems, as well as strategic expansion into the areas of Cell & Gene Therapy and MedTech and geographic expansion into Asia.
The sale of BioPhorum is the second successful realisation from Vespa Capital Fund II following the exit of Random42 to Graphite Capital.
Advisors to BioPhorum and Vespa Capital included Deloitte (David Jones/Amar Shah), DLA Piper (Yunus Maka) and PwC (Joel Smith).